Jenscare Scientific Co (HKSE:09877) ROCE % : -17.51% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Jenscare Scientific Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Jenscare Scientific Co's annualized ROCE % for the quarter that ended in Jun. 2024 was -17.51%.

Jenscare Scientific Co ROCE % Historical Data

The historical data trend for Jenscare Scientific Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jenscare Scientific Co ROCE % Chart

Jenscare Scientific Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-84.37

-61.23

-31.59

-28.37

Jenscare Scientific Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			-11.25	-54.41	-25.73	-30.50	-17.51

Jenscare Scientific Co ROCE % Calculation

Jenscare Scientific Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-414.492	/	( ( (1598.386 - 63.358)	+	(1451.545 - 64.184) )	/ 2 )
	=	-414.492	/	( (1535.028	+	1387.361)	/ 2 )
	=	-414.492	/	1461.1945
	=	-28.37 %

Jenscare Scientific Co's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-227.418	/	( ( (1451.545 - 64.184)	+	(1266.566 - 55.687) )	/ 2 )
	=	-227.418	/	( ( 1387.361	+	1210.879 )	/ 2 )
	=	-227.418	/	1299.12
	=	-17.51 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Jenscare Scientific Co (HKSE:09877) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Jenscare Scientific Co ROCE % Related Terms

Thank you for viewing the detailed overview of Jenscare Scientific Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Jenscare Scientific Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jenscare Scientific Co Ltd (HKSE:09877) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 777 Binhai 4th Road, Block 5, B Area, Hangzhou Bay New Area, Zhejiang Province, Ningbo, CHN

Website

https://www.jenscare.com

Jenscare Scientific Co Ltd is a China-based company mainly engaged in the manufacturing and research and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure.

Executives

Shanghai Jiachen Investment Co.,ltd	2201 Interest of corporation controlled by you
Li Hui	2501 Other
Lv Shiwen	2501 Other
Ningbo Dixiang Venture Capital Co., Ltd.	2201 Interest of corporation controlled by you
Shanghai Shidi Industrial Development Co., Ltd.	2501 Other
Ningbo Sangdi Investment Management L.p. (limited Partnership)	2101 Beneficial owner
Ningbo Linfeng Biotechnology Co., Ltd.	2101 Beneficial owner
Pan Fei	2201 Interest of corporation controlled by you
Hainan Yize Medical Technology Co., Limited	2201 Interest of corporation controlled by you
Hainan Maidi Enterprise Management L.p. (limited Partnership)	2101 Beneficial owner
Hainan Hualing Investment L.p. (limited Partnership)	2101 Beneficial owner
Hangzhou Chende Investment Partnership (limited Partnership)	2101 Beneficial owner
Ningbo Mukang Venture Capital Partnership (limited Partnership)
Li Hui

Jenscare Scientific Co Headlines

No Headlines